Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system

Cancer Research

Volumn 57, Issue 17, 1997, Pages 3759-3764

  Light, Benjamin W ^a   Yu, Wei Dong ^a   McElwain, Mariann C ^a   Russell, Derrick M ^a   Trump, Donald L ^a   Johnson, Candace S ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9,10 SECOCHOLESTA 5,7,10(19),16 TETRAEN 23 YNE 1,3,25 TRIOL; CALCITRIOL; CISPLATIN; VITAMIN D DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CALCIUM BLOOD LEVEL; CELL CYCLE; CELL CYCLE S PHASE; CLONOGENIC ASSAY; CYTOTOXICITY; DNA CONTENT; DNA SYNTHESIS INHIBITION; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CALCITRIOL; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; MICE; MICE, INBRED C3H;

EID: 0030880944     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. 3. Proc. Natl. Acad. Sci. USA, 78: 4990-4994, 1981.
2. 3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Res., 56: 3570-3576, 1996.
3. 3 induced differentiation in a human promyelocytic leukemia cell line HL-60: receptor mediated maturation to macrophage-like cells. J. Cell Biol., 98: 391-398, 1984.
4. 3 analogue EB1089. Eur. J. Cancer, 32A: 842-848, 1996.
5. 3. Cancer Res., 47: 21-25, 1987.
6. 3 on the morphology of human breast cancer cell line BT-20. Differentiation, 40: 63-69, 1989.
7. 5. J. Natl. Cancer Inst., 89: 212-218, 1997.
8. 3 prolongs survival time of leukemic mice. Proc. Natl. Acad. Sci. USA, 87: 3929-3932, 1990.
9. Colston, K. W., Chander, S. K., Mackay, A. G., and Coomes, R. C. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem. Pharmacol., 44: 693-702, 1993.
10. 3. Cancer Res., 54: 4057-4064, 1994.
11. 3 on primary cultures of human prostatic cells. Cancer Res., 54: 805-810, 1994.
12. 3 analog in a squamous cell carcinoma model system. Mol. Cell. Differ., 3: 31-50, 1995.
13. 3. Cell Proliferation, 27: 37-46, 1994.
14. 3 on human T lymphocyte activation and proliferation: a cell cycle analysis. J. Immunol., 135: 2279-2286, 1985.
15. 3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res., 55: 2822-2830, 1995.
16. 3 in HL60 cells. Cancer Res., 56: 264-267, 1996.
17. Sherman, S. E., and Lippard, S. J. Structural aspects of platinum anticancer drug interactions with DNA. Chem. Rev., 87: 1153-1181, 1987.
18. Chu, G. Cellular responses to cisplatin. J Biol. Chem., 269: 787-790, 1994.
19. Howle, J. A., and Gale, G. R. cis-Dichlorodiammineplatinum (II): persistent and selective inhibition of deoxyribonucleic acid synthesis in vivo. Biochem. Pharmacol., 19: 2757-2762, 1970.
20. 2 inhibit DNA synthesis in cultured L1210 leukemia cells. Biochem. Biophys. Res. Commun., 112: 555-563, 1983.
21. Roberts, J. J., and Thomson, A. J. The mechanism of action of antitumor platinum compounds. Prog. Nucleic Acid Res. Mol. Biol., 22: 71-133, 1979.
22. Pinto, A. L., and Lippard, S. J. Sequence-dependent termination of in vitro DNA synthesis by cis-and trans-diamminedichloroplatinum(II). Proc. Natl. Acad. Sci. USA, 82: 4616-4619, 1985.
23. 2 phase and cell death induced by cisplatin. J. Natl. Cancer Inst., 82: 749-755, 1990.
24. 1 or S phase. Mutat. Res., 293: 161-172, 1993.
25. Donaldson, K. L., Goolsby, G. L., and Wahl, A. F. Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int. J. Cancer, 57: 847-855, 1994.
26. Johnson, C. S., Chang, M-J., and Yu, W-D. Synergistic enhancement by interleukin-1α of cisplatin-mediated antitumor activity in RIF-1 tumor-bearing C3H/HeJ mice. Cancer Chemother. Pharmacol., 32: 339-346, 1993.
27. Braunschweiger, P. G., Johnson, C. S., Kumar, N., Ord, V., and Furmanski, P. Antitumor effects of recombinant human interleukin-1α in RIF-1 and Panc02 solid tumors. Cancer Res., 48: 6011-6016, 1988.
28. Braunschweiger, P. G., Jones, S. A., Johnson, C. S., and Furmanski, P. Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1. Cancer Res., 51: 5454-5460, 1991.
29. Chang, M-J., Yu, W-D., Reyno, L. M., Modzelewski, R. A., Egorin, M. J., Erkmen, K., Vlock, D. R., Furmanski, P., and Johnson, C. S. Potentialion by interleukin 1α of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model. Cancer Res., 54: 5380-5386, 1994.
30. Vindelov, L. L., Christensen, I. J., and Nissen, N. I. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry, 3: 323-327, 1983.
31. Bikle, D. D., and Pillai, S. Vitamin D, calcium, and epidermal differentiation. Endocr. Rev., 14: 3-19, 1993.
32. Reichel, H., Koeffler, H. P., and Norman, A. W. The role of the vitamin D endocrine system in health and disease. N. Engl. J. Med., 320: 980-981, 1989.
33. Davies, M. High-dose vitamin D therapy: indications, benefits and hazards. In: P. Walter, G. Brubacher, and H. Stahelin (eds.), Elevated Dosages of Vitamins, pp. 81-86. Lewiston, NY: Hans Huber, 1989.
34. Zhou, J-Y., Norman, A. W., Lubbert, M., Collins, E. D., Uskokovic, M. R., and Koeffler, H. P. Novel vitamin D analogs that modulate leukemic cell growth and differentiation with little effect on either intestinal calcium absorption or bone calcium mobilization. Blood, 74: 82-93, 1989.
35. Anzano, M. A., Smith, J. M., Uskokovic, M. R., Peer, C. W., Mullen, L. T., Letterio, J. J., Welsh, M. C., Shreder, M. W., Logsdon, D. L., Driver, C. L., Brown, C. C., Roberts, A. B., and Sporn, M. B. 1α,25-dihydroxy-16-ene-23-yne-26,27-hexafluoro-cholecalciferol Ro24-5531, a new deltanoid vitamin D analogue for prevention of breast cancer in the rat. Cancer Res., 54: 1653-1656, 1994.
36. Bikle, D. D., Gee, E., and Pillai, S. Regulation of keratinocyte growth, differentiation, and vitamin D metabolism by analogs of 1,25-dihydroxyvilamin D. J. Invest. Dermatol., 101: 713-718, 1993.
37. Dusso, A. S., Negrea, L., Gunawardhana, S., Lopes-Hilker, S., Finch, J., Mori, R., Nishii, Y., Slatopolsky, E., and Brown, A. J. On the mechanism for the selective action of vitamin D analogs. Endocrinology, 128: 1687-1692, 1991.
38. 3: differential effects on leukemia cell growth, differentiation and intestinal calcium absorption. Cancer Res., 50: 6857-6864, 1990.
39. Christen, R. D., Hom, D. K., Porter, D. C., Andrews, P. A., MacLeod, C. L., Hafstrom L., and Howell, S. B. Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J. Clin. Invest., 86: 1632-1640, 1990.
40. Isaacs, J. T., Isaacs, W. B., Feitz, W. F. J., and Scheres, J. Establishment and characterization of seven Dunning rat prostate cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate, 9: 261-281, 1986.
41. Begg, A. C. Principles and practices of the tumor growth delay assay. In: R. F. Kallman (ed.), Rodent Tumor Models in Experimental Cancer Therapy, pp. 114-121. New York: Pergamon Press, 1987.